KR850001573B1 - Preparation of bileacide condensed with amino acid - Google Patents

Preparation of bileacide condensed with amino acid Download PDF

Info

Publication number
KR850001573B1
KR850001573B1 KR1019840000118A KR840000118A KR850001573B1 KR 850001573 B1 KR850001573 B1 KR 850001573B1 KR 1019840000118 A KR1019840000118 A KR 1019840000118A KR 840000118 A KR840000118 A KR 840000118A KR 850001573 B1 KR850001573 B1 KR 850001573B1
Authority
KR
South Korea
Prior art keywords
amino acid
acid
condensed
bile acid
bile
Prior art date
Application number
KR1019840000118A
Other languages
Korean (ko)
Other versions
KR850005451A (en
Inventor
박언식
지영수
Original Assignee
주식회사 대웅제약
윤영환
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 대웅제약, 윤영환 filed Critical 주식회사 대웅제약
Priority to KR1019840000118A priority Critical patent/KR850001573B1/en
Publication of KR850005451A publication Critical patent/KR850005451A/en
Application granted granted Critical
Publication of KR850001573B1 publication Critical patent/KR850001573B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/22Cyclohexane rings, substituted by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Steroid Compounds (AREA)

Abstract

A bile acid I (R1=R2=H, OH; R3 = H, alkyl, phenyl or substituted phenyl; X = COOH, CH2SO3H) condensed with an amino acid was prepared. Thus, bile acid was reacted with KOH to form a bile calcium phosphate, which was reacted with alkylchloroformate to give an anhydro-mixture of bile acid. TEA salt condensed with amino acid was prepd. from TEA salt of amino acid II in a nonpolar solvent such as toluene, bentene, methylenechloride and dichloroethane. The TEA salt condensed with amino acid was then dissolved in a non-polar solvent and passed through dried HCl gas to give I.

Description

아미노산 축합 담즙산의 제조방법Method for preparing amino acid condensed bile acid

본 발명은 일반식(Ⅱ)인 아미노산의 트리에틸아민염과 일반식(Ⅲ)인 담즙산을 축합시켜 일반식(Ⅰ)인 아미노산 축합 담즙산을 제조하는 방법이다.The present invention is a method for producing amino acid condensed bile acids of general formula (I) by condensing triethylamine salts of amino acids of general formula (II) and bile acids of general formula (III).

Figure kpo00001
Figure kpo00001

여기서 R1, R2는 수소, 하이드록실기를, R3는 수소, 알킬, 페닐 또는 치환된 페닐기를, X는 -COOH, -CH2SO3H기를 TEA는 트리에틸아민을 표시한다.Where R 1 and R 2 represent hydrogen, a hydroxyl group, R 3 represents hydrogen, alkyl, phenyl or a substituted phenyl group, X represents a -COOH, -CH 2 SO 3 H group and TEA represents triethylamine.

상기 일반식(Ⅰ)의 물질은 이미 공지된 물질로서 그 제조방법도 F.Cortess A.Norman, A.F.Hoffmann, L. Lack 등에 의하여 공지되어 있다.The substance of general formula (I) is a known substance, and its preparation method is also known by F. Cortess A. Norman, A. F. Hoffmann, L. Lack and the like.

이들 공지된 방법을 살펴보면Looking at these known methods

1) F. Cortess 등의 방법에 따르면 트리포밀콜린산의 카르복실기를 할로겐화제 로 처리하여 반응성이 좋은 트리포밀콜린산할라이드를 제조한 후 아미노산과 반응시켜 아미노산 축합트리포밀콜린산을 제조하고 하이드록실기의 보호기인 포밀기를 가수분해하여 아미노산 축합 담즙산을 제조하였으나 본 방법은 반응 공정이 긴고 수율이 낮은 단점을 갖고 있다.1) According to the method of F. Cortess et al., The carboxyl group of triformylcholine acid is treated with a halogenating agent to prepare a reactive triformylcholine halide, and then reacted with an amino acid to prepare an amino acid condensed triformylcholine acid, and a hydroxyl group. The amino acid condensed bile acid was prepared by hydrolyzing formyl group, which is a protecting group, but the method has a long reaction process and a low yield.

2) A. Norman 방법이나 A.F. Hoffmann 방법은 담즙산의 혼합산 무수물과 아미노산의 급속염을 물 또는 알콜을 용매로 하여 반응시켜 목적 물질인 아미미산 축합담즙산을 제조하였으나 용매인 물 또는 알콜이 담즙산의 혼합산 무수물을 가수분해시켜 유리담즙산을 생성시키므로 목적물질의 수율의 감소는 물론 목적물질로부터 부생물질인 유리담즙산을 제거하기 위하여 이온교환수지를 사용하는 등의 분리방법이 복잡하고 수율도 60-80%로 낮기 때문에 공업적으로 실시할 수 없다.2) A. Norman method or A.F. In the Hoffmann method, amimic acid condensed bile acids were prepared by reacting mixed acid anhydrides of bile acids and rapid salts of amino acids with water or alcohol as a solvent. As a result, the separation method such as the use of an ion exchange resin to remove free bile acid, which is a by-product, from the target material is complicated, and the yield is low at 60-80%. Can't.

3) L. Lack가 개발한 방법은 담즙산과 아미노산의 금속염을 EEDQ ethoxy carbony 1-2-ethoxy-1, 2-dihydro quinoline) 존재하에서 반응시켜 제조하나 EEDQ의 시약이 너무 고가이고 용매로 사용한 알콜과 물이 반응중간체인 답즙산 혼합무수물과 반응하여 담즙유리산이 생성하므로 수율이 떨어지고 부반응 및 미반응 물질이 존재하며 외약용으로 사용할 수 있는 고순도의 목적물질을 제조할 수 없다.3) The method developed by L. Lack is prepared by reacting bile acid with a metal salt of amino acid in the presence of EEDQ ethoxy carbony 1-2-ethoxy-1, 2-dihydro quinoline, but the reagent of EEDQ is too expensive and used as a solvent. Since water reacts with bile acid mixed anhydride, which is an intermediate of reaction, bile free acid is produced, so the yield is low, side reactions and unreacted substances are present, and high purity target substances that can be used for external medicine cannot be prepared.

이러한 공지된 방법의 단점을 개선시킨 본 발명은 담즙산을 금속수산화물과 반응시켜 담즙산의 금속염을 제조한후 톨루엔, 벤젠, 메릴렌클로라이드 디클로로에탄 등에 혼탁시킨 후 피바로일클로라이드, 알킬클로로포르메이트 등과 반응시켜 담즙산의 카복실기를 반응성이 강한 혼합 무수물을 제조한 후 별도로 제조한 아미노산의 트리에틸아민염을 가하여 실온에서 반응시킨다. 본 반응은 비극성 용매에서 실시하여야 하며 이렇게 함으로써 극성용매사용시에 발생되는 담즙산의 혼합산무수물이 분해되어 유리답즙산이 생성되어 목적물질과 혼재하는 것을 최소한으로 줄일 수 있다. 또한 담즙산의 혼합무수물 제조시에 디에틸아민, 트리에틸아민, 피리딘, N, N-디메틸아닐린, 2, 6-루티딘 등의 염기를 사용함으로써 담즙산의 혼합무수물이 고수율로 생성되어 목적물질의 수율이 증가한다.The present invention, which improves the disadvantages of the known method, is prepared by reacting bile acid with a metal hydroxide to prepare a metal salt of bile acid, followed by turbidity in toluene, benzene, merylene chloride dichloroethane, and the like, followed by reaction with pivaloyl chloride, alkylchloroformate, and the like. Then, the carboxyl group of the bile acid is prepared to produce highly reactive mixed anhydride, and triethylamine salt of the amino acid prepared separately is added to react at room temperature. This reaction should be carried out in a non-polar solvent, so that the mixed acid anhydride of bile acid generated when using a polar solvent is decomposed to produce a free bile acid, thereby minimizing mixing with the target substance. In the preparation of mixed anhydrides of bile acids, mixed anhydrides of bile acids are produced in high yield by using bases such as diethylamine, triethylamine, pyridine, N, N-dimethylaniline, 2,6-rutidine, and the like. Yield increases.

반응이 완료되면 반응액을 농축시킨 후 잔유농축액에 n-헥산, 에테르 또는 이들 혼합액을 가하고 교반함으로써 목적 물질의 트리에틸아민염을 획득하며 트리에틸아민염을 비극성 용매에 용해시킨 후 건조시킨 HCl gas를 통과시킴으로써 아미노산 축합담즙산을 제조한다.After the reaction was completed, the reaction solution was concentrated and n-hexane, ether or a mixture thereof was added to the residue, followed by stirring to obtain triethylamine salt of the target substance. The triethylamine salt was dissolved in a nonpolar solvent and dried. The amino acid condensed bile acid is prepared by passing through.

[실시예 1]Example 1

KOH 1.3g을 용해시킨 물 50밀리미터에 우루소데스옥시콜린산 7.8그람(0.02몰)을 가하여 용해시킨 후 감압증류 및 건조하여 우루소데스옥시콜린산의 칼륨염을 제조하고 메틸렌클로라이드 100밀리미터에 현탁시키고 피바로일클로라이드 3그람, 2, 6-루티닌 2.5그람을 가하고 -10℃에서 반응액을 계속 교반하여 용액이 투명해지면 별도로 타우린 2.5그람과 TEA 3밀리미터를 메틸렌클로라이드 15밀리미터에 가하고 교반하여 제조한 타우린의 TEA염용액을 소량씩 적가한다. 적가가 끝나면 반용액을 30-40℃로 상승시킨 후 3시간 동안 교반한다. 반응이 완료되면 반응액이 20-30밀리리터가 될 때까지 감압증류하고 잔유액에 n-헥산, 에테르(1 : 2) 혼합용액을 가하고 빙옥중에서 2시간 교반하고 석출된 결정을 여과, 에테르로 세척한다. 여과물을 톨루엔에 용해한 후 빙옥중에서 교반하면서 건조시킨 HCl gas를 통과시키면 백색의 결정이 석출한다. 석출된 용액을 2시간 더 빙옥중에서 교반하여 여과하고 에테르로 세척한 후 오븐에서 50℃ 정도로 건조시키면 타우로 우루소데스옥시콜린산 8.5그람(85.4%)를 얻는다.Potassium salt of urodesoxycholic acid was prepared by dissolving 7.8 grams (0.02 mol) of urosodes oxycholine acid in 50 milliliters of KOH dissolved in 1.3 g of KOH, and then suspended in 100 millimeters of methylene chloride. After adding 3 grams of pivaloyl chloride, 2.5 grams of 2, 6-rutinine and continuously stirring the reaction solution at -10 ° C, the solution was made clear, and 2.5 grams of taurine and 3 millimeters of TEA were added to 15 millimeters of methylene chloride and stirred. A small amount of one taurine TEA salt is added dropwise. After the addition, the anti-solution is raised to 30-40 ℃ and stirred for 3 hours. After the reaction was completed, distilled under reduced pressure until the reaction solution became 20-30 milliliters, and n-hexane and ether (1: 2) mixed solution were added to the residue, stirred for 2 hours in ice jade, and the precipitated crystals were filtered and washed with ether. do. After dissolving the filtrate in toluene and passing through the dried HCl gas while stirring in ice jade, white crystals precipitate. The precipitated solution was stirred for 2 hours in ice jade, filtered, washed with ether and dried in an oven at 50 ° C. to obtain 8.5 grams (85.4%) of taurusodesoxycholic acid.

융점 : 188-197℃Melting Point: 188-197 ℃

[실시예 2]Example 2

KOH 1.3g을 용해시킨 물 50밀리리터에 리토콜린산 7.5그람(0.02몰)을 가하여 용해시킨 후 감압증류, 건조하여 리토콜린산의 칼륨염을 얻는다.7.5 grams (0.02 mol) of lithocholic acid was added to 50 milliliters of KOH 1.3 g of water in which KOH was dissolved, followed by distillation under reduced pressure and drying to obtain a potassium salt of lithocholic acid.

이것을 메틸렌클로라이드 100밀리미터에 현탁시킨 후 실시예 1의 방법에 따라 조작하면 타우로리액콜린산 7.8그람(81.1%)을 얻는다.This was suspended in 100 millimeters of methylene chloride and operated in accordance with the method of Example 1 to obtain 7.8 grams (81.1%) of taurolycholic acid.

융점 : 220-225℃Melting Point: 220-225 ℃

Claims (4)

일반식(Ⅲ)인 담즙산을 KOH로 담즙산의 칼륨염을 제조한 후 파바로일클로라이드, 알킬클로로포르메이트 등을 반응시켜 답즙산의 혼합무수물을 제조하고 톨루엔, 벤젠, 메틸렌클로라이드, 디클로로에탄 등의 비극성용매내에서 아미노산의 TEA염(Ⅱ)을 반응시켜 아미노산 축합 담즙산의 TEA 염을 제조하고 비극성 용매에 용해한 후 건조 HCl gas를 통과하여 일반식(Ⅰ)인 아미노산 축합 담즙산을 제조하는 방법After preparing the potassium salt of bile acid with KOH of bile acid of general formula (III), reacting with pavaroyl chloride, alkylchloroformate, etc. to prepare mixed anhydride of bile acid, and toluene, benzene, methylene chloride, dichloroethane, etc. TEA salt of amino acid condensed bile acid by reaction of amino acid TEA salt (II) in a non-polar solvent, dissolved in a non-polar solvent and passed through dry HCl gas to produce amino acid condensed bile acid of general formula (I)
Figure kpo00002
Figure kpo00002
R1, R2는 수소, 하이드록실기를, R3는 수소, 알킬, 페닐 또는 치환된 페닐기를, X는 -COOH, CH2SO3H를, TEA는 트리에틸아민염을 표시한다.R 1 and R 2 represent hydrogen, a hydroxyl group, R 3 represents a hydrogen, alkyl, phenyl or substituted phenyl group, X represents -COOH, CH 2 SO 3 H, and TEA represents a triethylamine salt.
특허청구범위 1항에서 축합 반응시에 벤젠, 톨루엔, 메틸렌클로라이드 디클로로에탄 등의 비극성 용매를 사용하는 방법. 단, 상기 4종류의 용매에 국한하지 않는다.Method of using a non-polar solvent such as benzene, toluene, methylene chloride dichloroethane during the condensation reaction in claim 1. However, it is not limited to the above four kinds of solvents. 특허청구범위 1항에서 아미노산 축합 담즙산의 TEA염을 결정화시에 n-헥산, 에테르 이들의 혼합용매를 사용하는 방법.A method of using a mixed solvent of n-hexane and ether in crystallization of TEA salt of amino acid condensed bile acid in claim 1. 특허청구범위 1항에서 아미노산 축합 합미산의 TEA염으로부터 목적물질인 일반식 (Ⅰ)을 제조시에 TEA염을 비극성 용매에 녹인 후 건조 HCl gas를 통과시켜 제조하는 방법.Method of preparing the general formula (I) as a target substance from the TEA salt of amino acid condensation synthesized acid in claim 1 by dissolving the TEA salt in a non-polar solvent and passing through a dry HCl gas.
KR1019840000118A 1984-01-13 1984-01-13 Preparation of bileacide condensed with amino acid KR850001573B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019840000118A KR850001573B1 (en) 1984-01-13 1984-01-13 Preparation of bileacide condensed with amino acid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019840000118A KR850001573B1 (en) 1984-01-13 1984-01-13 Preparation of bileacide condensed with amino acid

Publications (2)

Publication Number Publication Date
KR850005451A KR850005451A (en) 1985-08-26
KR850001573B1 true KR850001573B1 (en) 1985-10-19

Family

ID=19232598

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019840000118A KR850001573B1 (en) 1984-01-13 1984-01-13 Preparation of bileacide condensed with amino acid

Country Status (1)

Country Link
KR (1) KR850001573B1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1765406A4 (en) * 2004-05-21 2012-11-28 Mediplex Corp Delivery agents for enhancing mucosal absorption of therapeutic agents
KR102421414B1 (en) * 2021-09-28 2022-07-18 주식회사 에이.비.아이 Method for preparing bile comprising high purity taurochenodeoxycholic acid

Also Published As

Publication number Publication date
KR850005451A (en) 1985-08-26

Similar Documents

Publication Publication Date Title
SU629880A3 (en) Method of obtaining 7-d-(-)-2-formyloxy-2-(4-acyloxyphenylacetamido)-cephalosporanic acids or salts thereof
KR850001573B1 (en) Preparation of bileacide condensed with amino acid
EP0018415A1 (en) Process for producing alkyl 4-(alkoxy methyl phosphinoyl)butyrates and alkyl-(2-amino-4-(alkoxy methyl phosphinoyl)) butyrates
EP0272462B1 (en) Process for preparing ursodeoxycholic acid derivates and their inorganic and organic salts having therpeutic activity.
US4036833A (en) 7-[(5'-N-methylthioacetamido)-adipoamido] cephalosporin derivatives
US3741948A (en) Process for the preparation of n-protected - alpha - l-glutamyl - s -benzyl-l-cysteinylglysines
US3803202A (en) Process for the production of 2-cyano-3,4,5,6-tetrahalogenbenzoic acid alkyl esters
US4178306A (en) Preparation of N-(phosphonoacetyl)-L-aspartic acid
US3966825A (en) Process for preparing β-nitroethanethiol
SU828962A3 (en) Method of preparing 2-/4-(4-chlorobenzeneaminoethyl)-phenoxy/-2-methylpropionic acid
US3622619A (en) Biphenyl compounds
US4179464A (en) Preparation of N-(phosphonoacetyl)-L-aspartic acid
KR880001831B1 (en) Process for the preparation of n-phosphonomethylglycine
SU825509A1 (en) Method of preparing n-alpha-tert-butyloxycarbonyl-n-im-tritylhistidine
KR860000346B1 (en) 3alpha.7beta-dihydroxy-5beta-cholanoic acid
KR820000881B1 (en) Process for preparing thizolidine derivatives
FI62541C (en) NOW FOERFARANDE FOER ATT SELECTIVE FRAMSTAELLA ESTRIOL-16ALFA17BETA DIHEMISUKINAT
KR850001698B1 (en) Process for the preparation of 2-dialkylamino-2-phenyl-n-buthyl-3',4',5'-trimethoxybenzoic derivatives
JPH04297450A (en) Production of thiomalic acid
SU697510A1 (en) Method of preparing 4-sulfanylamido-6-methoxypyrimidine
US3882131A (en) Process for preparing 4,4-disulphoxy-diphenyl-(2-pryidyl)-methane derivatives
JPS58135840A (en) 2,3-difluoro-6-nitrophenol
KR910002282B1 (en) Process for the preparation of inden acetic acid
KR820000210B1 (en) Process for preparation of -oxo-1,1'-biphenyl-4-butanoic acid
US4895679A (en) Process for production of chenodeoxycholic acid and novel intermediates useful for the process

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19991001

Year of fee payment: 15

LAPS Lapse due to unpaid annual fee